Comprehensive Guide to 2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine
Table of Contents
- Product Overview & Specifications
- Key Applications in Pharmaceutical Research
- Practical Usage Scenarios
- Industry Client Success Stories
- Request Customized Solutions
Product Overview & Specifications
| Parameter | Specification | Competitor A | Competitor B |
|---|---|---|---|
| CAS Number | 160996-34-5 | Same | Same |
| Purity | ≥99.5% (HPLC) | 98.0-99.0% | 97.5-98.5% |
| Storage | 2-8°C, inert atmosphere | Ambient | 4-10°C |
Key Applications in Pharmaceutical Research
This heterocyclic compound is critical for:
- Intermediate in kinase inhibitor development
- Building block for JAK/STAT pathway modulators
- Synthesis of anticancer agents targeting EGFR mutations
Practical Usage Scenarios
Case 1: Non-Small Cell Lung Cancer Drug Development
Used in third-generation EGFR-TKI synthesis with 85% improved yield compared to alternative intermediates…
Case 2: Chronic Myeloid Leukemia Treatment
Key component in BCR-ABL1 inhibitor production demonstrating 92% target binding efficiency…
Industry Client Success Stories
1. Shanghai PharmaTech Co., Ltd. (2023)
Developed novel BTK inhibitor using our compound:
- Reduced synthesis steps from 12 to 8
- Achieved 99.2% purity in final API
- Accelerated IND submission timeline by 4 months
2. Berlin BioResearch GmbH (2024)
Scaled production of JAK2 inhibitor:
- 500kg batch production success
- Consistent impurity profile <0.3%
- Met stringent EMA documentation requirements
Request Customized Solutions
Contact our technical team for:
- Bulk pricing (1kg+ quantities)
- GMP-grade manufacturing options
- Custom synthesis projects
Email: info@vivalr.com
Phone: (86) 15866781826


评论
目前还没有评论。